WuXi Biologics

Waardering

K/W (TTM)

26,22

K/W (verwacht)

17,74

Winst per aandeel

HK$ 1,34

Koers/boekwaarde

2,65

Bèta

0,58

Kerncijfers

Omzet (TTM)

HK$ 21,79 mld

EBITDA

HK$ 7,92 mld

Winstmarge

22,53%

Rendement eigen verm. (ROE)

11,64%

Omzetgroei

17,20%

Uitstaande aandelen

4.136.396.936

Dividend

Dividendrendement

—

Dividend p/a

—

Uitkeringsratio

0,00%

Over WuXi Biologics

WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People's Republic of China, North America, Europe, Singapore, Japan, South Korea, Australia, and Brazil. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and manufacturing organization platforms, including WuXiBody, SDArBodY, T cell engager, Tumor Associated Antigens (“TAA”) mAb Technology, Single B Cell Cloning Technology, WuXia, WuXiUP, WuXiUI, and WuXiHigh. It engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, production and sales of medicals, and biologics clinical and manufacturing services; research and development in relation to biologics; international sales contracting service; vaccine contract development and manufacturing organization (CDMO) and related business; development, production, and distribution of biotechnological products; and engages in investment and material supplier activities. WuXi Biologics (Cayman) Inc. was incorporated in 2014 and is headquartered in Wuxi, China.